Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gigacloud Technology Inc (GCT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Gigacloud Technology IncTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Gigacloud Technology Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Gigacloud Technology Inc trades at $52.01 (market cap $1.84B), while State Street SPDR S&P Biotech ETF trades at $159.13. Which is the better fit depends on your goals.

GCTXBI
Market Cap
$1.84B
Sector
TechnologyBroad Market / Factor
52-Week High
$53.25$164.28
52-Week Low
$25.44$86.92
Enterprise Value
$1.97B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gigacloud Technology Inc

GigaCloud Technology (GCT) trades at $51.68, up 0.06% on the day, with a bullish technical outlook supported by moving averages and strong support at $50. The company reported Q2 2026 EPS of $1.16, beating estimates, and maintains a net income margin of 10.65%. Revenue growth is projected to rise from $1.29B in 2025 to $1.5B in 2026, while analyst sentiment is positive with a 66.7% buy rating.

The stock presents a compelling opportunity due to consistent earnings beats, robust profitability metrics like a 32.34% ROE, and attractive valuation with a P/E of 12.25. Key risks include reliance on B2B furniture logistics, competitive pressures, and potential margin compression from higher costs. Institutional confidence is bolstered by a $120M buyback program announced in Q2 2026.

State Street SPDR S&P Biotech ETF

XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.

The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.

Returns comparison

Trailing returns across standard periods

About Gigacloud Technology Inc

Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.

Read more on GCT

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI